Ethier C R, Coloma F M, de Kater A W, Allingham R R
Department of Mechanical Engineering, University of Toronto, Ontario, Canada.
Invest Ophthalmol Vis Sci. 1995 Nov;36(12):2466-75.
To extend the retroperfusion technique to allow the delivery of drugs into Schlemm's canal in enucleated human eyes and to use this technique to gain insights into the function of the inner wall of Schlemm's canal.
Using our previously developed retroperfusion technique, the anterior chamber of enucleated human eyes was held at a small negative pressure (-0.75 mm Hg), and fluid was allowed to flow retrograde from the limbal vessels, through the collector channels, and into Schlemm's canal. In this manner, the sulfhydryl agent N-ethyl maleimide (NEM) or the fixative agent glutaraldehyde was delivered to the inner wall of Schlemm's canal in normal and glaucomatous human eyes. Facility changes caused by retroperfusion were measured and correlated with histologic studies of the inner wall of Schlemm's canal.
Retroperfusion effectively delivers fluid from the scleral surface into the lumen of Schlemm's canal. Retroperfusion with vehicle alone does not alter facility or change outflow pathway morphology. Retroperfusion with NEM causes an approximately 35% facility increase and concomitant inner wall openings. Retroperfusion with glutaraldehyde in normal eyes and eyes with primary open-angle glaucoma causes a facility decrease of 53% and 64%, respectively, and localized fixation of the inner wall of Schlemm's canal. The magnitude of the facility changes caused by retroperfusion were similar to those seen using conventional forward perfusion of NEM and glutaraldehyde.
Retroperfusion is a viable technique for the delivery of drugs or other agents into Schlemm's canal in enucleated human eyes. Retroperfusion-induced changes in outflow facility are correlated strongly with morphologically observed alterations in inner wall structure. The majority of outflow resistance is localized to the inner wall of Schlemm's canal or the immediately adjacent 10-microns region of the juxtacanalicular tissue in normal eyes and in eyes with primary open-angle glaucoma. Inner wall giant vacuoles and pores likely persist for sometime, even after fixation at zero or negative pressure.
扩展眼后灌注技术,以便将药物输送到摘除的人眼球的施莱姆管中,并利用该技术深入了解施莱姆管内壁的功能。
使用我们先前开发的眼后灌注技术,将摘除的人眼球前房维持在较小的负压(-0.75毫米汞柱),使液体从角膜缘血管逆行流动,通过集液管,进入施莱姆管。通过这种方式,将巯基试剂N-乙基马来酰亚胺(NEM)或固定剂戊二醛输送到正常人和青光眼患者眼球的施莱姆管内壁。测量眼后灌注引起的房水流畅度变化,并将其与施莱姆管内壁的组织学研究相关联。
眼后灌注有效地将液体从巩膜表面输送到施莱姆管腔。仅用赋形剂进行眼后灌注不会改变房水流畅度或改变流出途径形态。用NEM进行眼后灌注会使房水流畅度增加约35%,并伴有内壁开口。在正常眼和原发性开角型青光眼眼中用戊二醛进行眼后灌注分别导致房水流畅度降低53%和64%,以及施莱姆管内壁的局部固定。眼后灌注引起的房水流畅度变化幅度与使用传统的NEM和戊二醛正向灌注时观察到的变化幅度相似。
眼后灌注是一种将药物或其他试剂输送到摘除的人眼球施莱姆管中的可行技术。眼后灌注引起的流出流畅度变化与内壁结构形态学观察到的改变密切相关。在正常眼和原发性开角型青光眼眼中,大部分流出阻力位于施莱姆管内壁或紧邻的近管组织10微米区域。即使在零压力或负压下固定后,内壁巨大液泡和孔隙可能仍会持续存在一段时间。